Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
-
Media Release
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD… -
Key Release
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto… -
Statement
Europe talks health sovereignty — now it must deliver
-
Story People and Culture
Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure
In the ever-evolving world of STEM, where innovation and discovery are to the forefront, the stories of women who have made their mark are both inspiring and essential. Today, we're shining a spotlight on two dedicated Novartis employees who have chosen to begin their careers in manufacturing operations, paving the way for others to follow.
-
Key Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation… -
Media Release
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of… -
Key Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)… -
Media Release
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients… -
Story Patient Perspectives
Marc’s story: Raising awareness of elevated Lp(a) in cardiovascular disease
-
Media Release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause… -
Media Release
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-… -
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board…
-
Media Release
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD… -
Key Release
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto… -
Key Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation… -
Media Release
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of… -
Key Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)… -
Media Release
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients… -
Media Release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause… -
Media Release
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-… -
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board… -
Media Release
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
Die Aktionärinnen und Aktionäre genehmigten die 28. Dividendenerhöhung in Folge. Für 2024 wird die Dividende auf CHF 3.50 (+6,1%) je Aktie erhöht, was einer Rendite von 3,5% entspricht1Die… -
Media Release
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III… -
Media Release
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5…
-
Key Release
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto… -
Key Release
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation… -
Key Release
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI)… -
Key Release
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +12% (kWk1, +11% USD), das operative Kernergebnis1 verbesserte sich um +22% (kWk, +19% USD)Das Umsatzwachstum… -
Key Release
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from… -
Key Release
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with… -
Key Release
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029Strong momentum in the business with 8 in-market brands with USD 3bn+ to… -
Key Release
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III… -
Key Release
Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +10% (cc1, +9% USD) with core operating income up +20% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+… -
Key Release
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +10% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +20% (kWk, +17% USD)Das Umsatzwachstum… -
Key Release
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4… -
Key Release
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm,…
-
Featured News
Official partner of the Eurovision Song Contest 2025
We’re thrilled to announce that Novartis, a proudly Swiss company, is an official partner of the Eurovision Song Contest 2025, hosted in our headquarters city of Basel, Switzerland.
-
Featured News
Novartis employs creative deal structure to establish Borealis Biosciences – divests legacy Chinook site, invests to form new company and engages in R&D collaboration
Novartis announced it has partnered with Versant Ventures (Versant) to form Borealis Biosciences (Borealis), an independent, discovery-stage biotechnology company based in Vancouver, Canada, focused on developing next-generation xRNA-based medicines for kidney diseases. xRNA, a core technology platform for Novartis, can target the body’s natural mRNA to modulate the production of proteins that cause disease.
-
Featured News
Our next era
Novartis poised to expand impact on human health as it begins next era.
-
Featured News
Novartis’ Giving & Volunteering wins ACCP’s 2023 Corporate Social Impact Team of the Year Award
-
Featured News
Creating positive social change through volunteering
Over 1 billion people volunteer worldwide, sharing their skills and experience, providing support within their communities, and offering emergency assistance to those in need. On International Volunteer Day (December 5), we join forces with the UN to recognize the tireless work of all volunteers and the contributions that they make.
-
Featured News
World Sight Day 2022: Raising awareness on the importance of eye health
Through the Avoidable Blindness Program, Novartis is working with partners to strengthen eye health in sub-Saharan Africa.
-
Featured News
Novartis Hematology: Working to help ensure patients are getting the access they need
Developing treatments for blood cancers and serious blood disorders is important, but it is only part of the equation. We also need to help ensure those who may need our therapies can get them.
-
Featured News
From the Heart
-
Featured News
Novartis Co-Creating Impact Summit 2021
Over 1,800 delegates came together at the annual Co-Creating Impact Summit to explore how understanding ‘impact’ is a crucial step in ensuring business makes a positive contribution to the world.
-
Featured News
Raising awareness of prostate cancer during Movember
Despite advancements in care, prostate cancer is one of the most frequently diagnosed cancers around the world. This Movember, we’re focused on raising awareness of prostate cancer.
-
Featured News
Sound Up for Lung Cancer
It’s time to change the conversation. Patient inspired and community led, Sound Up aims to empower people affected by lung cancer in raising the volume to vocally self-advocate.
-
Featured News
World Sight Day 2021
Novartis is working with partners around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care.
-
Statement
Europe talks health sovereignty — now it must deliver
-
Statement
Novartis statement on Maximum Fair Price for Entresto
-
Statement
Violence against innocent people runs counter to our work to improve human health
-
Statement
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
-
Statement
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody.
-
Statement
Novartis provides support for Moroccan earthquake victims
-
Statement
GT005 (PPY988): Development Program in Geographic Atrophy
-
Statement
Novartis statement on filing of Inflation Reduction Act lawsuit
-
Statement
Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Statement
European Commission (EC) adopts decision endorsing CHMP recommendation to revoke the conditional marketing authorization for Adakveo® (crizanlizumab)
-
Statement
CHMP recommends revoking the conditional marketing authorization for Adakveo® (crizanlizumab)
-
Statement
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.
-
Pulse Update
Novartis presentation at J.P. Morgan Healthcare Conference 2025
-
Pulse Update
Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington’s disease
-
Pulse Update
Novartis receives FDA Breakthrough Therapy designation for Scemblix® in 1L CML
-
Pulse Update
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
-
Pulse Update
Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
-
Pulse Update
Novartis appoints Sloan Simpson as Global Head of Investor Relations
-
Pulse Update
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
-
Pulse Update
FDA approves Novartis Millburn facility for US commercial production of Pluvicto®
-
Pulse Update
Novartis completes FDA filing for approval of Millburn facility to support Pluvicto® launch
-
Pulse Update
Novartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
-
Pulse Update
Novartis receives FDA Fast Track designation for branaplam (LMI070) for the treatment of Huntington’s Disease
-
Pulse Update
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
-
Story People and Culture
Science in Motion: Autumn and Sabrina's Noteworthy Novartis Adventure
In the ever-evolving world of STEM, where innovation and discovery are to the forefront, the stories of women who have made their mark are both inspiring and essential. Today, we're shining a spotlight on two dedicated Novartis employees who have chosen to begin their careers in manufacturing operations, paving the way for others to follow.
-
Story Patient Perspectives
Marc’s story: Raising awareness of elevated Lp(a) in cardiovascular disease
-
Story People and Culture
Parental leave – A leadership opportunity
At Novartis, we believe in the importance of balancing professional and personal responsibilities. This belief is embodied through our inclusive parental leave policy, which supports all our people in taking the time they need to be with their families during significant life events. To understand how this truly supports our colleagues we invited Sumeet, Global Head of Service Enablement & Governance, People Services & Solutions to share his story with us. -
Story People and Culture
Biologist to Head-hunter
I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.
-
Story Discovery
Addressing unmet needs for inherited neuromuscular diseases
Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.
-
Story People and Culture Careers
My journey to Novartis: Finding my purpose and passion
When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely different from what I was used to. But what sealed the deal for me was a conversation with my then manager who told me that the purpose I would feel and impact I would have would be unique. And she was right.
-
Story Access to Healthcare
Negative impact of the IRA on patient access to innovative treatments
At Novartis, we are constantly pushing the limits of science to develop and deliver transformative medicines that fight disease and help people live life on their terms.
-
Story People and Culture
Every number has a story – my journey to Novartis as a Refugee
The current refugee crisis is one of the world's greatest humanitarian challenges. Svitlana shares her story of her journey to Novartis and how her work as part of the Giving and Volunteering team is opening the doors to refugees and other marginalized groups and allowing our people to make a difference by helping those who are most vulnerable.
-
Story People and Culture
Is Diversity, Equity and Inclusion (DEI) really that important?
We think so and here are just some of the reasons why: we believe our workplace should reflect today’s emerging workforce; every culture needs diversity to thrive; and it supports fair treatment and opportunities for all our people.
-
Story Discovery
A legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.
-
Story People and Culture
A personal journey full circle, from curiosity about life on Earth to transformative therapies at Novartis
From curiosity about life on Earth to transformative therapies at Novartis. Michelle L Krishnan, Executive Director, MD PhD.
-
Story People and Culture
From black holes to AI driven drug discovery – collaboration wins the day
Dr Bülent Kızıltan, Global Head of AI & Computational Sciences
Novartis Financial Results - Q1 2025
Novartis announced the company’s financial results for the first quarter of 2025.
Novartis in Society Integrated Report 2024
The Novartis in Society Integrated Report provides an overview our business, strategy and performance, and describes how we create sustainable value for stakeholders and society.
Annual Report 2024
The Annual Report 2024, filed with the SIX Swiss Exchange in Switzerland, provides a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices.
Stories
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Events
Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage.
Get the latest news and updates from Novartis directly to your inbox.